###### Key messages

What is already known about this subject?
=========================================

-   Ubiquitin-proteasome system (UPS) pathway is recognised to be implicated in maintaining proper function of photoreceptor cells and the KLHL7 protein (a BTB-Kelch protein) has been found to play an important role in this process. However, there had been a paucity of literature with a handful of case reports suggesting associations between the *KLHL7* gene and autosomal dominant retinitis pigmentosa. In homozygous KLHL7 mutation, mid-periphery retinal changes were previously described.

What are the new findings?
==========================

-   In this study, we report novel macular findings observed in two young adults with homozygous KLHL7 gene mutation. The macular of the younger patient shows a depigmented area around the fovea giving a bull's-eye appearance while the older sibling shows a fibrotic ring around the fovea suggesting a more advanced pathology.

How might these results change the focus of research or clinical practice?
==========================================================================

-   This further strengthens the evidence of the implication and role of UPS in photoreceptor health. The newly described findings will add to the list of features for KLHL7 gene mutation, which will suggest the need for ophthalmic referrals as part of the clinical management of cases.

Introduction {#s1}
============

Heterozygous variants in the *KLHL7* gene have been causally associated with autosomal dominant retinitis pigmentosa (adRP) after linkage analysis in several families.[@R1] *KLHL7* encodes a 586 amino acid BTB-Kelch protein, which contains a BTB, BACK and a Kelch domain (with six Kelch motifs). It has earlier been identified to be a substrate recognition subunit of a CUL3-based ubiquitin ligase complex, through formation of a dimer via its BTB and BACK domains. The resultant E3 (cullin ubiquitin ligating enzyme) activity then polyubiquitinates target proteins for proteasome-mediated degradation. Although the exact biological function of KLHL7 is currently unknown, it is widely expressed in rod photoreceptor cells.[@R4] It is proposed that failure to form the E3 ligase complexes could result in accumulation of substrate proteins in photoreceptor cells, with their eventual demise and consequential retinal degeneration.[@R4]

The adRP caused by heterozygous *KLHL7* variants is late onset (\>50 years of age), with better preservation of vision and rod function (demonstrated by the lower annual rate of decline in 31 Hz Flicker) than that of a typical patient with RP (3% vs 10%).[@R3]

Biallelic *KLHL7* gene variants have been reported to cause a severe multisystem disorder which overlaps Bohring-Opitz syndrome (BOS) and Crisponi syndrome. To date, 11 patients have been reported in two papers. Briefly, reported systemic features include severe to profound learning difficulties, microcephaly, feeding and swallowing difficulties, hypotonia and joint contractures including camptodactyly. The facial gestalt is somewhat variable but often includes exophthalmos, nevus flammeus, micro/retrognathia, anteverted nares, hypertelorism and a high-arched narrow palate.[@R5] In 2016, Angius *et al* described the effect of biallelic *KLHL7* mutations on the retina in two young children: aged 4 (c.1258C\>T/p.Arg420Cys) and 6 (c.1022delT/p.Leu341Trpfs\*9) years, both showed signs of early-onset RP.[@R7] In the same paper, it was noted that other causes for a Crisponi syndrome phenotype such as variants in the *CRLF1* or *L1FR* genes were not found to cause retinal changes.

Here, we report novel visual symptoms and signs in two young adults clinically diagnosed with the overlapping BOS/Crisponi syndrome expanding the phenotypic presentation of homozygous *KLHL7* gene variants to include a distinctive maculopathy.

Case presentation {#s2}
=================

Research procedures were performed in accord with institutional guidelines and the Declaration of Helsinki and informed consent was obtained from the patient's parents.

Patients 1 and 2 are siblings born to a non-consanguineous family with no significant family history including that of RP. They were diagnosed with the overlapping clinical phenotype of Bohring-Opitz and Crisponi syndromes with features reported by Bruel *et al*.[@R5] Genetic testing identified homozygous truncating variants NM_001031710.2:c.1051C\>T (p.Arg351\*) in the *KLHL7* gene by whole exome sequencing in both siblings while each parent was found to be heterozygous for the truncating variant.

Clinical presentation {#s3}
=====================

At the time of presentation to the ophthalmology department, patient 1 was a 21-year-old man and patient 2 was a 19-year-old woman. Both siblings developed respiratory distress requiring intubation and surfactant at birth, and had significant feeding difficulties, with reflux, requiring fundoplication and gastrotomy. They have similar facial features, including a glabellar nevus flammeus, high-arched pallet with broad alveolar ridges, hypertelorism, thin upper lip, low-set dysplastic ears and microcephaly. They also have a BOS posture with fixed contractions at the elbows and fingers and poor vision.

Ophthalmic symptoms and signs {#s4}
=============================

The parents reported that their 21-year-old son had difficulties with depth perception, in particular, reaching out for objects at a closer distance than they were actually placed. He could fix and follow an object but not read any of the Cardiff Cards. He appeared to see better if he turned his head to view an object held directly in front of him. His younger sister could read the Cardiff Card D held at 50 cm but appeared to struggle more with her peripheral field on a functional level. Both patients had severe mental disabilities prohibiting any detailed testing of visual function. Both patients had normal cornea, lens and anterior chamber examination. Peripheral retinal signs were remarkably similar and symmetrical in both patients, with bilateral confluent hypopigmented/pale yellow lesions (reminiscent of, but larger than, deposits seen in Stargardt disease) in the mid-periphery. The far periphery was unaffected in both siblings ([figure 1](#F1){ref-type="fig"}). In the macular of the younger sibling there was a depigmented area around the fovea giving a bull's-eye appearance. In the older male there was a fibrotic ring around the fovea suggesting a more advanced pathology ([figure 2](#F2){ref-type="fig"}). The optic discs were again a paler colour in the older sibling with a ring of peripapillary atrophy. Retinal arterioles were generally attenuated in both siblings. No pigmented bone spicules were noted and there was no evidence of inflammation or vitritis.

![Fundal images of patient 2. (A) The fundal image of patient 2, which shows confluent hypopigmented/pale yellow lesions in the mid-periphery. The optic disc appears to be pale with a ring of atrophy and vessels appear attenuated. (B) The far periphery of retina of the same eye of the patient, note that the hypopigmented lesions do not extend to the far periphery.](bmjophth-2018-000234f01){#F1}

![Fundal images demonstrating macular features in biallelic KLHL7 mutation. (A) The fundal image of patient 2 (younger sibling) which shows a depigmented area around the fovea giving a bull's-eye appearance. (B) (patient 1) A fibrotic ring around the fovea which may suggest a more advanced pathology.](bmjophth-2018-000234f02){#F2}

Ophthalmic examination of both parents, aged 60 years, demonstrated good visual acuities. The mother had diabetes and changes in association with diabetic retinopathy, while the father had a completely normal eye examination. There were no signs of RP in either parent.

Discussion {#s5}
==========

Here, we described the retinal findings in a sibling pair of young adults with homozygous truncating mutations NM_001031710.2:c.1051C\>T (p.Arg351\*) in the *KLHL7* gene and a systemic phenotype matching the BOS-Crisponi syndrome. There has only been one other report of early-onset RP in two children aged 4 and 6 years with biallelic mutations in the *KLHL7* gene.[@R7]

There appears to be a phenotype-genotype correlation in the *KLHL7* gene.[@R4] The three substitutions resulting in late-onset adRP were found in the BACK domain, which is required for CUL3 binding with BTB domain. In these cases, the central macula area was well preserved. The biallelic mutations causing the more severe early-onset form of RP in both the previously described cases and our two older siblings were in the Kelch domain (hypothesised to form salt bridges with nearby proteins), resulting in either a premature termination codon producing an incomplete Kelch domain from the KLHL7 protein, or missense mutations resulting in loss of stabilisation, with diminished substrate binding. There are no published studies which demonstrate the functional effect of the current mutation (pArg351), but we hypothesise similar loss of function of KLHL7 protein as a possible mechanism due to its position in the Kelch domain and the premature termination of translation ([figure 3](#F3){ref-type="fig"}).

![Figure demonstrating KLHL7 protein monoallelic gene mutations are located at the BACK domain, which with BTB domain will interfere with CUL3 binding, which usually polyubiquitinates target proteins for proteasome-mediated degradation. This has been found to be associated with autosomal dominant retinitis pigmentosa (RP). Biallelic gene mutations (gene mutation in current paper highlighted in red, p.Arg351) are found in the Kelch domain with clinical phenotypes of BOS/CS and CS/CSS1 syndrome. adRP, autosomal dominant retinitis pigmentosa; BOS, Bohring-Opitz syndrome; CISS1, old-induced sweating syndrome type 1; CS, Crisponi syndrome.](bmjophth-2018-000234f03){#F3}

The observed retinal changes in our two cases had some overlap with those described in the earlier reports with well-circumscribed hypopigmented lesions that appeared clinically reminiscent of lipofuscin deposits, mainly in the mid-periphery area ([table 1](#T1){ref-type="table"}). However, we also observed a distinctive maculopathy with a bull's-eye appearance progressing to a fibrotic/atrophic ring in the older sibling ([figure 2](#F2){ref-type="fig"}). Macular features were present in both siblings bilaterally. This is the first report of the ocular phenotype of adults with recessive KLHL7 variants and it is possible that the older age may have contributed to these differences and represent a more advanced phenotype. Such changes may be hypothesised to be due to the accumulation of toxic substrates due to the lack of E3 activity which polyubiquitinates target proteins for proteasome-mediated degradation. Interestingly, the heterozygous or monoallelic mutation of the same gene did not show any evidence of retinal dysfunction in either of the parents in this study or in previous studies.[@R1] It appears therefore that haploinsufficiency is not sufficient alone to disrupt the ubiquitin-proteasome pathway and produce a clinical phenotype but complete lack of functional protein is necessary.

In conclusion, this paper is the first to describe the ocular phenotype in adults with a biallelic KLHL7 stop mutation (Arg 351) and expands the clinical findings to include a distinctive maculopathy with associated loss of visual function.

###### 

Retinal findings of families with KLHL7 mutation

  Literature                     Systemic associations                                                  Patient cohort                                                                    Retinal findings                                                                                                                                                                                                                                                                                                                                                          Genetic mutation
  ------------------------------ ---------------------------------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Friedman *et al* [@R1]         Not reported                                                           24 patients from a six-generation Scandinavian family                             Changes of retinitis pigmentosa: retinal degeneration and bone spicules                                                                                                                                                                                                                                                                                                   Heterogeneous c.449G/A (p.S150N), in exon 6 of the *KLHL7* gene
  Hugosson *et al* [@R2]         Not reported                                                           11 patients from a single family from the Swedish retinitis pigmentosa register   In early stages---normal fundiIn late stages---scattered bone corpuscular pigment, waxy pale disc, thinning of the retina and attenuated retinal blood vesselsFirst study with full-field ERG: varying degree of photoreceptor degeneration during long-term follow-up, with some family members manifesting late onset and preserved rod function until late in life     Heterozygous exon 6 change (c.458C\>T)
  Wen *et al* [@R3]              Nil                                                                    5 unrelated families referred to the Retina Foundation of the Southwest           Fundi showed classic signs of RP, including bone spicule pigmentation, arteriolar attenuation and waxy optic pallorBest corrected visual acuity was 20/50 or better in at least one eye up to age 65 yearsStatic and kinetic visual fields showed concentric constriction to central 10°--20° by age 65 yearsDecline rate of 3% per year in cone 31 Hz flicker response   Heterozygous c.458C\>T (p.Ala153Val), c.449G\>A (p.Ser150Asn) and c.457G\>A (p.Ala153Thr)
  Angius *et al* [@R7]           Crisponi syndrome (CS)/cold-induced sweating syndrome type 1 (CISS1)   2 children who has been diagnosed with CS/CISS1 syndrome, 4 and 6 years of age    Fundi: abnormal appearance of the macula, attenuated arteriolar vessels, retinal pigmentary changes                                                                                                                                                                                                                                                                       Homozygous c.1258C\>T/p.Arg420Cys and c.1022delT/p.Leu341
  Heng *et al* (current paper)   BOS-Crisponi syndrome                                                  2 siblings from non-consanguineous parents from the UK                            Fundi: soft confluent pale yellow lesions in mid-periphery, attenuated vessels, waxy optic disc, bull's-eye maculopathy                                                                                                                                                                                                                                                   Homozygous c.1051C\>T (p.Arg351\*)

BOS, Bohring-Opitz syndrome; ERG, electroretinography; RP, retinitis pigmentosa.
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